Fig. 2: Histopathologic and molecular predictors of ORR12 in PREDIX LumB. | Nature Communications

Fig. 2: Histopathologic and molecular predictors of ORR12 in PREDIX LumB.

From: Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

Fig. 2: Histopathologic and molecular predictors of ORR12 in PREDIX LumB.The alternative text for this image may have been generated using AI.

Forest plot for the primary endpoint of ORR12 according to histopathologic biomarkers and PET/CT SUVmax as continuous variables (A), and molecular biomarkers subgroup analysis (B) in PREDIX LumB. Odds ratios were estimated using logistic regression with two-sided Wald tests, interaction effects were evaluated using two-sided likelihood ratio tests, and no adjustment for multiple comparisons was applied. Source data are provided as a Source Data file.

Back to article page